The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease...

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Recurrent somatic mutations in SRSF2, an RNA splicing gene, are found in a significant number of myelodysplastic syndrome (MDS) patients.
• The clinical and biological implications of SRSF2 mutations in MDS require further investigation.

Purpose of the Study:

• To investigate the clinical and biological characteristics of MDS patients with SRSF2 mutations.
• To determine the prognostic impact and stability of SRSF2 mutations during disease progression.

Main Methods:

• Somatic mutation analysis was performed on 233 MDS patients.
• Clinical data, including survival, were analyzed in relation to SRSF2 mutation status.
• Sequential samples from 66 patients were used to assess mutation stability over time.

Main Results:

• SRSF2 mutations were identified in 14.6% of MDS patients, associated with male sex and older age.
• SRSF2 mutations frequently co-occurred with RUNX1, IDH2, and ASXL1 mutations.
• Patients with SRSF2 mutations exhibited inferior overall survival, especially in lower-risk groups, potentially due to age association.
• SRSF2 mutations were stable throughout the disease course, with no acquisition of novel mutations in SRSF2-wild patients.

Conclusions:

• SRSF2 mutation is a distinct feature in MDS, associated with specific clinical and biological characteristics.
• SRSF2 mutations are stable during MDS progression and may not directly drive disease evolution.
• The prognostic impact of SRSF2 mutations is likely influenced by patient age.